Butorphanol in Pain Following Ablation for Hepatic Tumor
- Conditions
- Visceral PainMicrowave AblationHepatic Tumor
- Interventions
- Drug: normal saline
- Registration Number
- NCT06031129
- Lead Sponsor
- Bibo Wang
- Brief Summary
The objective of this investigation was to evaluate the influence of Butorphanol on postoperative pain mitigation in patients undergoing microwave ablation for hepatic tumor. Employing a rigorously designed multicentral, randomized, and placebo-controlled format, patients subjected to microwave ablation were assigned randomly to either Butorphanol (experimental group) or normal saline (control group). Primary outcomes encompassed intraoperative pain levels assessed through patient-driven evaluation utilizing a 10-point visual analog scale (VAS). Secondary outcomes included postoperative pain levels at the 6-hour mark (VAS) and comprehensive pain assessment outcomes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
patients performing Microwave Ablation sign the informed consent
Patients with a body mass index > 30 kg/m2 a history of depression opioid dependence poorly controlled hypertension (systolic blood pressure > 180 mmHg) myocardial infarction severe liver disease significant abdominal pain before surgery patients with sensory system or language dysfunctions who could not cooperate to complete the scale pregnant women.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Butorphanol Butorphanol - normal saline normal saline -
- Primary Outcome Measures
Name Time Method Visceral Pain during the surgery VAS score of visceral pain
- Secondary Outcome Measures
Name Time Method Visceral Pain 6-hour after surgery VAS score of visceral pain
Trial Locations
- Locations (1)
Jinling Hosipiatl
🇨🇳Nanjing, Jiangsu, China